Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
37.25
+0.04 (0.11%)
Apr 25, 2025, 12:42 PM EDT - Market open
Exelixis Employees
Exelixis had 1,147 employees as of December 31, 2024. The number of employees decreased by 163 or -12.44% compared to the previous year.
Employees
1,147
Change (1Y)
-163
Growth (1Y)
-12.44%
Revenue / Employee
$1,890,759
Profits / Employee
$454,461
Market Cap
10.43B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,147 | -163 | -12.44% |
Dec 31, 2023 | 1,310 | 87 | 7.11% |
Dec 31, 2022 | 1,223 | 269 | 28.20% |
Dec 31, 2021 | 954 | 181 | 23.42% |
Dec 31, 2020 | 773 | 156 | 25.28% |
Dec 31, 2019 | 617 | 133 | 27.48% |
Dec 31, 2018 | 484 | 112 | 30.11% |
Dec 31, 2017 | 372 | 85 | 29.62% |
Dec 31, 2016 | 287 | 172 | 149.57% |
Dec 31, 2015 | 115 | 17 | 17.35% |
Dec 31, 2014 | 98 | -129 | -56.83% |
Dec 31, 2013 | 227 | 53 | 30.46% |
Dec 31, 2012 | 174 | -26 | -13.00% |
Dec 31, 2011 | 200 | -183 | -47.78% |
Dec 31, 2010 | 383 | -293 | -43.34% |
Dec 31, 2009 | 676 | 0 | - |
Dec 31, 2008 | 676 | -59 | -8.03% |
Dec 31, 2007 | 735 | 84 | 12.90% |
Dec 31, 2006 | 651 | 101 | 18.36% |
Dec 31, 2005 | 550 | 33 | 6.38% |
Dec 31, 2004 | 517 | -56 | -9.77% |
Dec 31, 2003 | 573 | 23 | 4.18% |
Dec 31, 2002 | 550 | -21 | -3.68% |
Dec 31, 2001 | 571 | 214 | 59.94% |
Dec 31, 2000 | 357 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
EXEL News
- 4 weeks ago - Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire
- 4 weeks ago - Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025 - Business Wire
- 5 weeks ago - Exelixis Growth Continues with Big Money Boosts - FXEmpire
- 2 months ago - Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March - Business Wire
- 2 months ago - Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday? - Benzinga
- 2 months ago - Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program - Business Wire
- 2 months ago - Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025 - Business Wire
- 2 months ago - Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit - Business Wire